COMMUNIQUÉS West-GlobeNewswire

Taconic Biosciences Licenses Easi-CRISPR Technology from the University of Nebraska
20/04/2018
RENSSELAER, N.Y., April 20, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered mouse model and service solutions, has been granted a license to the Easi-CRISPR technology [...]
Summit Presents New 24-Week Analyses from PhaseOut DMD at the 2018 AAN Conference
20/04/2018
Summit Therapeutics plc ('Summit', or 'the Company') Summit Presents New 24-Week Analyses from PhaseOut DMD at the 2018 American Academy of Neurology Annual Meeting Data show correlation between decrease in muscle [...]
Cynata Therapeutics Completes Patent Application to Cover Cymerus™ Stem Cell Technology in the Treatment of Side Effects Related to CAR-T Therapy
20/04/2018
Initial data from preclinical study at the University of Massachusetts Amherst demonstrate Cymerus MSCs ameliorate the effects of cytokine release syndrome (CRS) and other related adverse reactions to CAR-T therapy [...]
Summit Presents New 24-Week Analyses from PhaseOut DMD at the 2018 American Academy of Neurology Annual Meeting
20/04/2018
Data show correlation between decreases in muscle damage and reduction in muscle inflammation in patients treated with ezutromid OXFORD, United Kingdom and CAMBRIDGE, Mass., April 20, 2018 (GLOBE NEWSWIRE) -- Summit [...]
Emerald Health Therapeutics Names DDB Canada Agency of Record
20/04/2018
Powerful partnership will create globally-recognized brands that deliver trust and confidence to responsible cannabis users VICTORIA, British Columbia, April 20, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics Inc [...]
Purepoint Uranium Completes Winter Program at Hook Lake Project
20/04/2018
TORONTO, April 20, 2018 (GLOBE NEWSWIRE) -- Purepoint Uranium Group Inc. (the “ Company ” or “ Purepoint ”) (TSX.V:PTU) today announced the completion of the latest winter program at its Hook Lake Project, a joint [...]
Clementia Initiates Phase 2 MO-Ped Trial for Palovarotene in Patients with Multiple Osteochondromas
20/04/2018
Global, Late-stage Trial for Ultra-rare Skeletal Disease with No Approved Treatments MONTREAL, April 20, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ: CMTA ), a clinical-stage company innovating new [...]
Clementia lance l’essai MO-Ped de phase 2 pour évaluer le palovarotene chez les patients atteints d’ostéochondromes multiples
20/04/2018
Un essai de stade avancé, d’envergure mondiale, sur une maladie squelettique ultra-rare sans traitement approuvé MONTRÉAL, 20 avr. 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ: CMTA ), une société au [...]
Digirad Corporation to Release 2018 First Quarter Financial Results on May 1, 2018
20/04/2018
Conference Call and Webcast Set for 11:00 a.m. EDT SUWANEE, Ga., April 20, 2018 (GLOBE NEWSWIRE) -- Digirad Corporation (NASDAQ: DRAD ) will release financial results for its first quarter ended March 31, 2018, before [...]
Nexstim Plc to present at BioTrinity 2018 in London
20/04/2018
Press release, Helsinki, 20 April 2018, at 12 noon Nexstim Plc to present at BioTrinity 2018 in London Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), the targeted neuromodulation company developing and [...]
ELSALYS BIOTECH ANNOUNCES THE REGISTRATION OF ITS DOCUMENT DE BASE
20/04/2018
ELSALYS BIOTECH ANNOUNCES THE REGISTRATION OF ITS DOCUMENT DE BASE IN THE CONTEXT OF ITS PROPOSED INITIAL PUBLIC OFFERING ON THE PARIS EURONEXT GROWTH ® MARKET Lyon, FRANCE, 20 April 2018, ELSALYS BIOTECH, a new player [...]
ELSALYS BIOTECH ANNONCE L'ENREGISTREMENT DE SON DOCUMENT DE BASE
20/04/2018
ELSALYS BIOTECH ANNONCE L'ENREGISTREMENT DE SON DOCUMENT DE BASE DANS LE CADRE DE SON PROJET D'INTRODUCTION EN BOURSE SUR LE MARCHE EURONEXT GROWTH ® PARIS Lyon, FRANCE, le 20 avril 2018, ELSALYS BIOTECH, nouvel acteur [...]
CellaVision AB presents the first quarter 2018 on May 3 at 11:00 CET
20/04/2018
The information was submitted to the public on April 20, 2018 at 8:20 CET CellaVision AB (publ) will publish the interim report for the first quarter on May 3, 2018 at 8:20 CET. The report will be available at www. [...]
Shire plc : Rule 2.9 Announcement
20/04/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 20 April 2018 [...]
New Novartis analyses at AAN show siponimod's efficacy on disability and cognition in secondary progressive MS patients
20/04/2018
Analyses of the EXPAND study showed that siponimod (BAF312) reduced the risk of disability progression largely disassociated from relapses in patients with secondary progressive multiple sclerosis (SPMS)[1] In EXPAND, [...]
Basilea reports presentations of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
20/04/2018
Basel, Switzerland, April 20, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that a broad range of posters and presentations on the antifungal isavuconazole (Cresemba ® ) and the antibiotic ceftobiprole ( [...]
MDxHealth (R): SelectMDx Included in Dutch DRG Reimbursement System
20/04/2018
NEWS RELEASE Further progress of strategy to expand market for SelectMDx ® IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, April 20, 2018 - MDxHealth SA ("MDxHealth, or the "Company"), (Euronext: MDXH.BR), a world leader [...]
MDxHealth (R) : SelectMDx inclus dans le système de remboursement néerlandais DRG
20/04/2018
COMMUNIQUÉ DE PRESSE Poursuite de la stratégie d'expansion du marché de SelectMDx® IRVINE, CA, et HERSTAL, BELGIQUE - 07h00 CEST, 20 avril 2018 - MDxHealth SA (« MDxHealth », ou la « Société ») (Euronext : MDXH.BR), [...]
FDA Accepts Veloxis’s Supplemental New Drug Application for the De Novo Indication for ENVARSUS XR®
19/04/2018
Company Release no. 11/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 19 April 2018 FDA Accepts Veloxis’s Supplemental New Drug Application for the De Novo Indication for ENVARSUS XR ® Veloxis Pharmaceuticals A/S [...]

Pages